Legally Untreatable — A New Category of Long Stay Patient?

1994 ◽  
Vol 39 (7) ◽  
pp. 433-435 ◽  
Author(s):  
Michael P. Chan ◽  
G. Neil Conacher

The case is presented of a young and violent chronic schizophrenic patient whose symptoms respond to antipsychotic medication but who was recorded, at a time when he was deemed competent, as expressing a wish that he should not be given antipsychotic treatment. Under the present usage of the Ontario Mental Health Act, substitute consent givers are bound by such a “prior competent wish” and this patient must now be considered one of a growing group of “legally untreatable” psychotic patients.

1959 ◽  
Vol 105 (441) ◽  
pp. 1112-1118
Author(s):  
G. A. Dransfield ◽  
M. W. Browne

Recent work, such as that of Moore and Martin (1957), has shown that reserpine is of value in the treatment of the chronic schizophrenic patient. Attention has however been drawn to the incidence of side-effects in this form of treatment. These side-effects have limited the application of the drug and have also led to the search for a related substance, of similar clinical effect but without the troublesome toxic effects. This present trial is of a substance, deserpidine (Harmonyl, Abbott Laboratories), which it was thought would fulfil these requirements. The isolation of this alkaloid was first reported in 1955 by Stoll and Hofman, and it has subsequently been identified as 11-desmethoxy-reserpine (Harrisson, 1955) which can be represented thus:


Psychiatry ◽  
1984 ◽  
Vol 47 (4) ◽  
pp. 324-332 ◽  
Author(s):  
Michael A. Selzer ◽  
Monica Carsky ◽  
Bruce Gilbert ◽  
William Weiss ◽  
Matthew Klein ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document